Tenders Are Invited For Medicinal Products For The Alimentary Tract And Metabolism – Drug With Active Substance Cerliponase Alfa 150 Mg, Infusion Solution

Medicinal Products For The Alimentary Tract And Metabolism – Drug With Active Substance Cerliponase Alfa 150 Mg, Infusion Solution. The Subject Of The Order Is Medicine With The Active Ingredient Cerliponase Alfa 150 Mg, Infusion Solution Pharmaceutical Form: Sol Inf 5 Ml/150 Mg+5 Ml Prepl.Solution (Medicine.Inj.Skl.) Administration: Intracerebroventricular Use The Medicine Cerliponase Alfa Belongs To The Group Of Medicines Known As Enzyme Replacement Therapies. It Is Used To Treat Patients With Neuronal Ceroid Lipofuscinosis Type 2 (Cln2), Also Known As Tripeptidyl Peptidase 1 (Tpp1) Deficiency. People With Cln2 Disease Lack Or Have Too Little Of An Enzyme Called Tpp1, Which Causes Substances Called Lysosomal Storage Substances To Build Up. In People With Cln2 Disease, These Substances Accumulate In Some Parts Of The Body, Especially In The Brain. This Drug Replaces The Missing Enzyme Called Tppa, Thereby Minimizing The Accumulation Of Lysosomal Storage Substances. This Medicine Works By Slowing Down The Progression Of The Disease. The Recommended Dose Is 300 Mg Of Cerliponase Alfa Administered Once Every Two Weeks By Intracerebroventricular Infusion. Estimated Need For The Mentioned Medicine For 24 Months Is 360 Mj (180 Packs Of 2X5ml/150Mg+1X5ml Prepl. Solution Or Equivalent). By Describing The Subject Of The Contract In Detail, The Contracting Authority Established The Minimum Requirements That It Requires To Be Observed For The Given Subject Of The Contract. In The Event That The Contracting Authority Used A Specific Manufacturer, Production Process, Brand, Patent, Type, Country, Region Or Place Of Origin Or Production In The Description Of The Subject Of The Contract, The Applicant May, In Accordance With § 42 Par. 9 Of The Act On Public Procurement To Submit An Offer Also For A Technical And Functional Equivalent.